Filter
185
Filtered Results: 185
Text search:
dolutegravir
Featured
Recommendations
22
New Publications
43
Language
Document type
No document type
87
Guidelines
43
Studies & Reports
34
Manuals
9
Strategic & Response Plan
5
Fact sheets
3
Infographics
2
Training Material
1
Situation Updates
1
Countries / Regions
Global
7
Argentina
7
South Africa
7
Malawi
5
Latin America and the Carribbean
5
Kenya
4
Brazil
4
Colombia
3
Africa
3
Namibia
3
Venezuela
2
South–East Asia Region
2
Botswana
2
Myanmar / Burma
2
Nepal
1
Thailand
1
Ukraine
1
Lesotho
1
Chile
1
Nigeria
1
Burkina Faso
1
Peru
1
Zimbabwe
1
Philippines
1
Guinea
1
Mozambique
1
Congo, Democratic Republic of
1
Western Pacific Region
1
Western and Central Europe
1
North America
1
Bolivia
1
Uganda
1
Central African Republic
1
Ethiopia
1
Chad
1
Zambia
1
Somalia
1
Authors & Publishers
Publication Years
Category
Policies & Guidelines HIV & TB
32
HIV & STI
18
TB
7
Drugs & Medical Equipment
5
COVID-19
4
Guidelines
4
Pediatrics
3
Humanitarian Crisis
3
Paediatrics
2
Women & Child Health
2
Studies & Reports
2
Statistics
2
Pharmacy & Technologies
2
Communicable Diseases
1
Hepatitis
1
Emergency Health Kits
1
Buruli Ulcer
1
Countries
1
Policies
1
Capacity Building
1
Other
1
Maternal Health
1
Primary Health Care
1
Neurology & Psychology
1
Reproductive Health
1
Toolboxes
Antiretroviral Treatment ART
28
Clinical Aspects, Treatment & Prevention
22
ART Drug Resistance
16
Treatment & Prevention
15
Treatment Guidelines HIV
14
General Reports
13
Children & Adolescents
13
Global
8
Reports & Studies
7
Prevention & Control
6
Universal Health Coverage UHC and 90-90-90 Strategy
6
Essential Medicines & Devices Lists
6
Reports & Studies Children HIV
6
Policies
5
Drug resistance
5
Clinical Aspects
4
Adults
4
Essential Medicines
4
General Aspects
4
Opportunistic Infections
3
HIV and COVID-19
3
Co-Morbidities (except TB)
3
Prevention of mother-to-child transmission (PMTCT)
3
TB/HIV Coinfection
3
HIV service delivery
3
Lobby and Advocacy
3
Eastern Europe and central Asia
3
HIV testing & services
2
Prevention Guidelines
2
International
2
Essential List
2
Country specific documents
2
Brazil
2
Rational use of Medicine
2
Argentina
2
Access to treatment and laboratory
2
Detection & Diagnosis
2
Postexposure Prophylaxis (PEP), Pre-Exposure Prophylaxis (PrEP)
2
Policies and guidelines
2
Depression
2
Eastern and Southern Africa
2
Drugs
1
Policies & Strategies
1
HIV support organizations
1
Childhood TB
1
Substance Use Disorders, Others
1
Schizophrenia
1
HIV
1
Others
1
Children
1
Health & Refugee
1
General
1
Laboratory
1
For General Public & Community
1
Global Impact: Socio-economic, health services, TB & HIV
1
Guidelines
1
Tips & Best Practice Examples
1
TB/HIV
1
Community Health Workers CHW
1
Colombia
1
Model Formulary
1
Mental Disorders
1
Situation Reports & Updates
1
General
1
Strategies & Roadmaps
1
Clinical Aspects & Diagnostics
1
West and central Africa
1
Health Worker
1
Drug resistant TB
1
Neurological Disorders
1
Substance Use Disorders & Addiction
1
Community Worker
1
Bipolar Affective Disorders
1
TB/HIV Global
1
Regions
1
Prophylactic Treatment
1
Training
1
HIV / AIDS
1
HIV and coinfection
1
Testing Guidelines
1
Epidemiology
1
Epidemiology
1
HIV in Key Populations
1
SEAR (South-east Asia Region)
1
MSF Essential Drugs - Practical Guidelines 2022
recommended
Practical guide intended for physicians, pharmacists, nurses and medical auxiliaries. This guide is not a dictionary of pharmacological agents. It is a practical manual intended for health professionals, physicians, pharmacists, nurses and health auxiliaries invoved in curative care and drug managem...
WHO
Considering programmatic implications of rising levels of HIV drug resistance: finalizing the Global Action Plan
Webinars 12 13 Dec 2016
Guía práctica de utilización destinado a médicos, farmacéuticos, enfermeros y auxiliares sanitario.
Technical Update
Areas of Africa endemic for Buruli ulcer (BU), caused by Mycobacterium ulcerans, also have a high prevalence of human immunodeficiency virus (HIV), with adult prevalence rates between 1% and 5% (Maps). However, there is limited information on the prevalence of BU–HIV coinfection....
The report provides a brief introduction to patents and licences and their effect on the market for antiretroviral (ARV) medicines. It gives an overview of the patent landscape with respect to a select number of ARV medicines in developing countries as of April 2014. The focus is primarily on those ...
Selection and Use of Essential Medicines 2021
recommended
The 23rd meeting of the WHO Expert Committee on Selection and Use of Essential Medicines was coordinated from Geneva, Switzerland, and held virtually from 21 June to 2 July 2021. The Committee considered 88 applications proposing additions, changes and deletions of medicines, medicine classes and fo...
This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of the opportunities for – and threats to – expand...
WHO operational handbook on tuberculosis: module 4: treatment: tuberculosis care and support
recommended
The consolidated guidelines are complemented by an operational handbook which is designed to assist with implementation of the WHO recommendations by Member States, technical partners and others who are involved in the management of patients with DR-TB. The WHO Operational Handbook on Tuberculosis, ...
Accessed on 04.04.2023
The Drugs for Neglected Diseases initiative (DNDi) is an international
non-profit organization that discovers, develops, and delivers safe,
effective, and affordable treatments for the most neglected patients
The Transformation Agenda (TA) ushered in an ambitious reform process intended to transform the World Health Organization (WHO) into an organization that is proactive, results-driven, accountable and which meets stakeholder expectations, towards transforming and improving public health services in t...
This policy brief describes key HIV viral load thresholds and the available viral load testing approaches for monitoring how well antiretroviral therapy is working for people living with HIV. It provides clarification for and elaborates upon the current treatment monitoring algorithm from the Consol...
This report makes clear that there is a path to end AIDS. Taking that path will help ensure preparedness to address other pandemic challenges, and advance progress across the Sustainable Development Goals. The data and real-world examples in the report make it very clear what that path is. It is not...
This status report shows how far we have come—and how much further we must go—if we hope to meet the global commitments to end AIDS in children. It offers a snapshot of global progress and permits an early assessment of the impact of the Global Alliance’s work.
About one fourth of the world’s population is estimated to have been infected with the tuberculosis (TB) bacilli, and about 5–10% of those infected develop TB disease in their lifetime. The risk for TB disease after infection depends on several factors, the most important being the person’s im...
The coronavirus outbreak that began in 2019 (COVID-19) threatens to reverse years of hard-won gains in preventing and treating HIV. Fragile health systems are further stressed as health workers navigate an increased client load and demands at work while also being concerned for their own health and ...
This document defines the framework for Malawi’s National HIV Programs. Considering public health benefits and risks, as well as funding and resource implications, deviations from these guidelines are not supported by the Ministry of Health.
PEPFAR Malawi’s Country Operational Plan (COP) 2021 reflects a culmination of strong interagency collaboration between the PEPFAR Malawi team, Government of Malawi (GoM), and civil society organizations (CSOs) to mitigate the devastating impacts of COVID-19 and sustain progress achieved over the l...
